Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GNVC was down $1.06 (47%) to $1.20 on 7.2 million shares on Thursday after
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury